Yun Zhong, an analyst from Wedbush, maintained the Buy rating on Wave Life Sciences. The associated price target remains the same with $18.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Yun Zhong has given his Buy rating due to a combination of factors related to Wave Life Sciences’ promising developments in their AATD treatment program. The upcoming data from the RestorAATion-2 study is anticipated to show significant improvements in AAT levels with repeat dosing, as suggested by preclinical findings. This could lead to positive stock reactions if human data aligns with these preclinical results.
Furthermore, the potential for higher doses to allow for reduced injection frequency could make WVE-006 a more attractive treatment option for patients. Additionally, the success of WVE-006 is expected to validate Wave Life Sciences’ RNA editing technology, paving the way for new AIMer programs targeting liver diseases and hypercholesterolemia, which are set to enter clinical trials in 2026. These factors collectively underpin the optimistic outlook and Buy rating for Wave Life Sciences’ stock.
In another report released yesterday, Oppenheimer also initiated coverage with a Buy rating on the stock with a $24.00 price target.